3 ms·
New Drug Development: Estimating entry from human clinical trials (2003) [pdf]
- gwern 13y ago"New Drug Development: Estimating entry from human clinical trials", Adams & Brantner 2003; excerpts: "This paper analyses a detailed data set on drugs in human clinical trials around the world between 1989 and 2002. The data provides information on the probabilities with which drugs successfully complete the different phases of the trials and the durations of successful completions. The paper shows that success rates and durations can vary substantially across observable characteristics of the drugs, including primary indication, originating company, route of administration and chemistry. It suggests that analysis of this type of data can help us to answer questions such as: Do AIDS drugs get to market faster? Do Biotech drugs have higher probabilities of getting to market? This paper provides some general statistics for analyzing these questions...Our basic summary is that approximately 1 in 8 drugs that entered Phase I are launched on the US market. Note that according to the FDA, only 1 in 1,000 drugs pass the preclinical stage and are proposed for testing in humans (FDA, 2002). However, almost half the R&D expenditures occur in the preclinical stage of development (Levy, 1999) Pharmaprojects contains information on 27,987 new branded drug entities that have reached the late stage development from 1980 to 2002. For the purposes of this study, we limited the sample size to the 3,328 drugs that have entered either Phase I, or Phase II, or Phase III of the human clinical trials somewhere in the world for the first time since 1989. On average, it takes just under 8 years for a drug to go from Phase I of human clinical trials to market launch in the US. The same figures for Phase II and Phase III drugs are 6.1 and 3.7 years respectively. More specifically, an average drug spends 1.7 years in Phase I, 2.4 years in Phase II, and 3.7 years in Phase III before launch. Graph 1 presents a graph showing the estimated duration for the drugs in the data set by their primary indication. While it takes just 5.5 years on average for HIV/AIDS drugs to get from Phase I to the market, it takes drugs for Parkinson’s disease almost twice that long to go through the same process. Drugs for arthritis also spend more than 9 years, and asthma drugs spend more than 8 years in clinical trials on average. HIV/AIDS, anti-hypertension, and leukemia cancer drugs are some drugs that spend less than 7 years in clinical development. Again, this result is suggestive, but more sophisticated analysis is necessary to determine whether more important drugs get to market faster, and why."
- icegreentea 13y agoSurely part of the discrepancy in timing is indirectly linked to "importance", since we typically include "lethality" and similar measures into what we consider important. Clearly a good chunk of the time spent in trial is to determine side-effects, contraindications and the like. Given that more "important" targets are also likely more "lethal" targets, then their bars for acceptable side-effects are surely going to be lower. I mean, who really cares if there's a potential for 5% of drug takers go blind, if the increase in survival rate over the current best option is sufficiently high.
- pinaceae 13y agostudy from 2003, a little bit has changed since then. but overall, it shows that using the market as a guiding principle for the selection of which drugs to develop works. it frees humans from making morally horrible choices. by being profit driven, drug development is automatically covering the diseases which have the highest number of patients and highest economic impact. the latter is difficult to stomach, but from a purely scientific standpoint, which overlaps with the market, a western life is indeed worth more than an african one. simple to prove, kill 3000 westerners and the world goes to war. kill 3000 ethopians and the world goes meh. it is impossible to target all diseases at the same time. also, through healthcare spending the world is signalling in cold, hard terms how much their health is worth to them. which leads to finite resources and, again, the horrible choice on what to try to cure. supply and demand, where demand is not only desire but backed by the economic means and will to spend it, works in this area. as for the speed of the approval process - better safe than sorry. the only way to make it faster would be larger human trials, but who exactly wants that?
- HarryHirsch 13y agoby being profit driven, drug development is automatically covering the diseases which have the highest number of patients and highest economic impact. Your faith in Mammon, the god of money, is touching, but unwarranted. There is malaria and schistosomiasis, these two are holding back development of the African continent; there is also the emerging threat of multidrug-resistant tuberculosis, yet there is preciously little research done into these because there is little money to me made. At least for Malaria we have the Gates Foundation. Meanwhile, the second most-sold medication in the US is a stomach acid blocker. If you don't think something is wrong there, I think something is wrong with you.
- pinaceae 13y agoplease read my comment again, you're missing my point. humanity is voting, through their wallets, who should be treated for what. as an individual you despise it from a moral standpoint, sure, but once you reach the level of treating billions far stronger and fundamental rules takes over. very similar to the vaccination debate where an individuals opinion should not be respected for a larger goal, a vaccinated herd of people.
- berntb 13y agoThere is a problem at the other end, after the clinical trials, if a problem is found in use. There were complaints about memory damage for Lipitor for over a decade, without public warnings (the warnings came recently, a while after the patents timed out). If this had been found in the human trials, I doubt it would have been let through. I do wonder if the large amount of money from selling the drug (a big bestseller) had influence on any decision... Nah, regulatory capture is a myth re the medical industry, they wouldn't sell out our health, would they?